Sanofi, Ferring deal

Ferring reacquired rights to desmopressin acetate (dDAVP) from Sanofi to treat nocturnal enuresis (bedwetting). The peptide-based synthetic analogue of vasopressin is available in tablet, nasal spray, rhinal tube and injectable formulations, all of which have FDA approval. Sanofi declined to provide additional details, and Ferring did not respond to requests for information. ...